Concise review: Guidance in developing commercializable autologous/patient-specific cell therapy manufacturing

Stem Cells Translational Medicine

Volumn 2, Issue 11, 2013, Pages 871-883

  Eaker, Shannon ^a,b   Armant, Myriam ^a,c   Brandwein, Harvey ^a,d   Burger, Scott ^a,e   Campbell, Andrew ^a,f   Carpenito, Carmine ^a,g   Clarke, Dominic ^a,h   Fong, Timothy ^a,i   Karnieli, Ohad ^a,j   Niss, Knut ^a,k   Van't Hof, Wouter ^a,l   Wagey, Ravenska ^a,m  

^a International Society for Cellular Therapy   (United States)

^b GE HEALTHCARE   (United States)

^c HARVARD UNIVERSITY   (United States)

^d PALL CORPORATION   (United States)

^e Advanced Cell and Gene Therapy   (United States)

^f Life Technologies   (United States)

^g LONZA   (United States)

^h Charter Medical Ltd   (United States)

ⁱ Progenitor Cell Therapy LLC   (United States)

^j MATAM Advanced Technology Park # 20   (Israel)

^k NOVARTIS PHARMA AG   (Switzerland)

^l ATHERSYS INC   (United States)

^m STEMCELL Technologies   (Canada)

more..

Author keywords

Cellular therapy; Clinical translation; Stem cell culture; Stem cells

Indexed keywords

ANTIBIOTIC AGENT; CYTOKINE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BATCH PROCESS; BIOREACTOR; CELL ADHESION; CELL DENSITY; CELL ISOLATION; CELL SUSPENSION; COMMERCIAL PHENOMENA; CRYOPRESERVATION; CULTURE MEDIUM; DRUG APPROVAL; DRUG MANUFACTURE; FUNCTIONAL ASSESSMENT; GOOD MANUFACTURING PRACTICE; HUMAN; ISOLATION PROCEDURE; MUTATION; PERFUSION; PROCESS DEVELOPMENT; PROTOCOL COMPLIANCE; REPRODUCIBILITY; RISK ASSESSMENT; STEM CELL CULTURE;

EID: 84886499737     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2013-0050     Document Type: Article

References (32)

1. Hibino N, Nalbandian A, Devine L et al. Comparison of human bone marrow mononuclear cell isolation methods for creating tissue-engineered vascular grafts: Novel filter system versus traditional density centrifugation method. Tissue Eng Part C Methods 2011;17:993-998.
2. Sowemimo-Coker SO, Andrade F, Kim A et al. A simple filtration system for red blood cell depletion and volume reduction in routine processing of human umbilical cord blood. Vox Sang 2009;96:138-145.
3. Hubel A. Advancing the preservation of cellular therapy products. Transfusion 2011; 51(suppl 4):82S-86S.
4. Hunt CJ. Cryopreservation of human stem cells for clinical application: A review. Transfus Med Hemother 2011;38:107-123.
5. Thirumala S, Goebel WS, Woods EJ. Clinical grade adult stem cell banking. Organogenesis 2009;5:143-154.
6. Burger S. Biopreservation stability considerations for cell therapy development and commercialization. BioPreservation Today 2009;1:4-5.
7. Clarke DM. Optimizing biopreservation yield: Steps to improving cryopreservation outcomes. BioPreservation Today 2009;1:6.
8. Mathew AJ. What is your viability assay really saying? BioPreservation Today 2009; 1:8.
9. Clarke DM, Yadock DJ, Nicoud IB et al. Improved post-thaw recovery of peripheral blood stem/progenitor cells using a novel intracellular-like cryopreservation solution. Cytotherapy 2009;11:472-479.
10. Gorfien SF, Campbell A, Vemuri MC. Design of culture media. In: Murray M-Y, ed. Comprehensive Biotechnology. 2nd ed. Burlington, VT: Academic Press; 2011:205-215.
11. Jayme DW. Serum-free and protein-free media. In: Stacey GN, Davis J, eds. Biological Medicines from Cell Culture. London, U.K.: Wiley; 2007:29-44.
12. Eibl R, Werner S, Eibl D. Bag bioreactor based on wave-induced motion: Characteristics and applications. Adv Biochem Eng Biotechnol 2010;115:55-87.
13. Singh V. Disposable bioreactor for cell culture using wave-induced agitation. Cytotechnology 1999;30:149-158.
14. Rowley J, Abraham E, Campbell A et al. Meeting lot-size challenges of manufacturing adherent cells for therapy. BioProcess Int 2012;10:16-22.
15. Abu-Absi NR, Kenty BM, Cuellar ME et al. Real time monitoring of multiple parameters in mammalian cell culture bioreactors using an in-line Raman spectroscopy probe. Biotechnol Bioeng 2011;108:1215-1221.
16. Tran CA, Burton L, Russom D et al. Manufacturing of large numbers of patient-specific T cells for adoptive immunotherapy: An approach to improving product safety, composition, and production capacity. J Immunother 2007;30:644-654.
17. Artym VV, Matsumoto K. Imaging cells in three-dimensional collagen matrix. Curr Protoc Cell Biol 2010;Chapter 10:Unit 10.18.1-18.20.
18. Fekete N, Rojewski MT, Furst D et al. GMP-compliant isolation and large-scale expansion of bone marrow-derived MSC. PLoS One 2012;7:e43255.
19. Fossett E, Khan WS. Optimising human mesenchymal stem cell numbers for clinical application: A literature review. Stem Cells Int 2012;2012:465259.
20. Fossett E, Khan WS, Longo UG et al. Effect of age and gender on cell proliferation and cell surface characterization of synovial fat pad derived mesenchymal stem cells. J Orthop Res 2012;30:1013-1018.
21. Sekiya I, Larson BL, Smith JR et al. Expansion of human adult stem cells from bone marrow stroma: Conditions that maximize the yields of early progenitors and evaluate their quality. STEM CELLS 2002;20:530-541.
22. Sotiropoulou PA, Perez SA, Salagianni M et al. Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. STEM CELLS 2006; 24:462-471.
23. Erickson IE, Kestle SR, Zellars KH et al. High mesenchymal stem cell seeding densities in hyaluronic acid hydrogels produce engineered cartilage with native tissue properties. Acta Biomater 2012;8:3027-3034.
24. Colter DC, Sekiya I, Prockop DJ. Identification of a subpopulation of rapidly self-renewing and multipotential adult stem cells in colonies of human marrow stromal cells. Proc Natl Acad Sci USA 2001;98:7841-7845.
25. Beck G, Schenerman M, Dougherty J et al. Raw material control strategies for bioprocesses. BioProcess Int 2009;7:18-33.
26. Shapiro HM. Practical Flow Cytometry. 4th ed. Hoboken, NJ: Wiley-Liss, 2003.
27. Chattopadhyay PK, Hogerkorp CM, Roederer M. A chromatic explosion: The development and future of multiparameter flow cytometry. Immunology 2008;125:441-449.
28. Maecker H, Trotter J. Selecting reagents for multicolor flow cytometry. Becton Dickinson Application Note 23-9538-01. Franklin Lakes, NJ: Becton Dickinson, 2008.
29. Mahnke YD, Roederer M. Optimizing a multicolor immunophenotyping assay. Clin Lab Med 2007;27:469-485
30. Perfetto SP, Ambrozak D, Nguyen R et al. Quality assurance for polychromatic flow cytometry. Nat Protoc 2006;1:1522-1530.
31. Bravery CA, Carmen J, Fong T et al. Potency assay development for cellular therapy products: An ISCT review of the requirements and experiences in the industry. Cytotherapy 2013;15:9-19 e19.
32. Bailey AM. Balancing tissue and tumor formation in regenerative medicine. Sci Transl Med 2012;4:147fs28.